Study of NXN 188 for the Treatment of Migraine With Aura
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
NXN-188 Dihydrochloride is being developed as an immediate release oral product for the
treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects
with a migraine history of aura.